ResearcherShihezi UniversityActive in the last 2 years

Yanli Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1685-4441; OpenAlex author ID A5063866148. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

Ultrasound-Triggered NPC1L1-Targeting Nanobubbles for Remodeling the Tumor Microenvironment in Pancreatic Cancer Chemoimmunotherapy. Last author DOI 10.1021/acsami.5c01194 ↗
Bufadienolides from Chansu Injection Synergistically Enhances the Antitumor Effect of Erlotinib by Inhibiting the KRAS Pathway in Pancreatic Cancer. Co-author DOI 10.3390/ph17121696 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Juanjuan Ou · 1 shared paper, 2025 · strength 0.28
- Paper Ultrasound-Triggered NPC1L1-Targeting Nanobubbles for Remodeling the Tumor Microenvironment in Pancreatic Cancer Chemoi… DOI 10.1021/acsami.5c01194 ↗
Dong Li · 1 shared paper, 2025 · strength 0.28
- Paper Ultrasound-Triggered NPC1L1-Targeting Nanobubbles for Remodeling the Tumor Microenvironment in Pancreatic Cancer Chemoi… DOI 10.1021/acsami.5c01194 ↗
Ketao Ma · 1 shared paper, 2024 · strength 0.22
- Paper Bufadienolides from Chansu Injection Synergistically Enhances the Antitumor Effect of Erlotinib by Inhibiting the KRAS … DOI 10.3390/ph17121696 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.